- Home
- UA vs VKTX Comparison
UA vs VKTX Comparison
Compare UA & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UA | VKTX |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.4B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | UA | VKTX |
|---|---|---|
| Price | $6.85 | $34.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $95.86 |
| AVG Volume (30 Days) | ★ 2.7M | 2.4M |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $22.96 |
| 52 Week High | $7.91 | $43.15 |
Technical Indicators
Market Signals| Indicator | UA | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.32 | 44.70 |
| Support Level | $5.87 | $34.03 |
| Resistance Level | $7.80 | $36.77 |
| Average True Range (ATR) | 0.31 | 2.05 |
| MACD | -0.01 | -0.66 |
| Stochastic Oscillator | 53.28 | 3.75 |
Price Performance
Historical ComparisonAbout UA Under Armour Inc. Class C
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.